Alzheimer's Assocation Research only
All of
  • Go to
  • Research Center
  • AAIC
  • Journal
  • Grants
  • TrialMatch
  • Press
  • Donate
  • Contact Us
Science and Progress
Clinical Trials
Funding and Collaboration
You can Help
Stay Current
Video and Resources

Text Size

Small text Medium text Large text

Research Grants 2016

To view an abstract, select an author from the vertical list on the left.

2016 Grants - Roy

Identifying Molecules that Attenuate APP and BACE-1 Interactions

Subhojit Roy, Ph.D.
University of California, San Diego
La Jolla, CA

2016 Collaboration 4 Cure (C4C) Grant

Can interfering with the interaction between APP and BACE-1 in nerve cells reduce beta-amyloid protein production?

The production of beta-amyloid protein in the brain can lead to the formation of amyloid plaques, a hallmark of Alzheimer’s disease. Beta-amyloid is produced from its parent protein, amyloid precursor protein (APP), but the cutting action of an enzyme called beta-secretase 1 (BACE-1). Although inhibiting BACE-1 activity is one way to reduce beta-amyloid production, the BACE-1 inhibitors investigated thus far have caused unwanted side effects because they cut other important proteins. An alternative approach to reducing beta-amyloid production is to prevent BACE-1 from physically interacting specifically with APP. BACE-1 and APP are produced inside the nerve cell and packaged into separate spherical containers called vesicles. These vesicles must meet up within the nerve cell for BACE-1 to act on APP and produce beta-amyloid. If the BACE-1 and APP-containing vesicles could be prevented from coming together inside nerve cells, then beta-amyloid would not be produced.

Research Plan
Dr. Subhojit Roy has developed a method that can track BACE-1 and APP-containing vesicles as they move inside nerve cells growing in a laboratory dish. This method uses fluorescent signals that light up only when BACE-1 and APP-containing vesicles come together inside nerve cells. The researchers will use this system to test whether specific drug-like molecules are effective at preventing the BACE-1 and APP-containing vesicles from meeting. The researchers will rapidly screen thousands of individual drug-like molecules to determine which ones inhibit the BACE1-APP interaction — an approach called high-throughput screening. Any molecules that are found to prevent the BACE-1 and APP-containing vesicles from interacting will be selected for further testing in animal studies.

These new methods may provide a way to quickly identify molecules that can prevent BACE-1 and APP-containing vesicles from coming together inside nerve cells—thus preventing beta-amyloid production. The novel drug candidates identified can then be further investigated as potential treatments to slow, halt or prevent Alzheimer’s disease.

Alzheimer's Association International Conference | July 16-20, 2017, London, England

Abstract Submissions Now Open

The Scientific Program Committee is now accepting submissions for poster
presentations, oral presentations and featured research sessions.